Double-ICI combinations [29, 35, 157] and multi-modality regimens [21, 28, 41] remain limited, with ctDNA, bTMB, IL-6 and AFP, CTC, ctDNA emerging as predictors, underscoring the broad applicability of tumor-related markers. The gene discussed is IL6; the disease is neoplasm.